YouTube · Q2 2026 · 2026-08-07
PFE · NYSE
Pfizer Inc.
Drug Manufacturers - General · United States
- Market cap (USD)
- US$157.65B
- Trailing P/E
- 36.39x
- Forward P/E
- 9.55x
- Quarterly revenue growth
- 2.6%
- Trailing net margin
- 6.8%
- Indicated dividend yield
- 6.2%
Snapshot 2026-09-20 · Latest financial period 2026-06-28 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-11-03 (provider estimate, not issuer-confirmed).
Company background
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company websiteQ2 2026
Go beyond the headline.
Comparable businesses
PFE peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | PFEPfizer Inc.Snapshot 2026-09-20Financial period: 2026-06-28 | NVONovo Nordisk A/SSnapshot 2026-09-20Financial period: 2026-06-30 | BMYBristol-Myers Squibb CompanySnapshot 2026-09-20Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$157.65B | US$191.03B | US$128.81B | US$159.92Bn=2 |
| Forward P/EProvider forward earnings estimate | 9.55x | 12.86x | 9.61x | 11.23xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 8.26x | — | 8.60x | — |
| Revenue growthLatest quarter vs prior-year quarter | 2.6% | 2.1% | 5.7% | 3.9%n=2 |
| Operating marginLatest reported quarter | 27.9% | 42.5% | 34.4% | 38.5%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 7.9% | — | 6.3% | — |
| Net debt / EBITDANet debt / trailing EBITDA | 2.04x | 0.55x | 1.80x | 1.17xn=2 |
| Debt / equityTotal debt / positive book equity | 0.74x | 0.63x | 2.02x | 1.33xn=2 |
| Trailing P/ETrailing twelve-month earnings | 36.39x | 10.73x | 13.89x | 12.31xn=2 |
| Price / bookPrice / positive book equity per share | 1.85x | 5.60x | 5.77x | 5.69xn=2 |
| EV / salesEnterprise value / trailing revenue | 3.29x | — | 3.31x | — |
| Earnings growthLatest quarter vs prior-year quarter | — | -20.6% | 153.1% | 66.2%n=2 |
| Gross marginTrailing twelve months | 74.7% | 82.0% | 71.7% | 76.8%n=2 |
| Net marginTrailing twelve months | 6.8% | 35.3% | 18.9% | 27.1%n=2 |
| Return on equityProvider trailing return; positive equity only | 5.0% | 59.8% | 46.6% | 53.2%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 19.6% | 11.4% | 16.5% | 14.0%n=2 |
| Dividend yieldIndicated annual dividend / price | 6.2% | 4.2% | 4.0% | 4.1%n=2 |
| Earnings payoutProvider trailing dividend payout | 226.3% | 44.5% | 55.3% | 49.9%n=2 |
| Current ratioCurrent assets / current liabilities | 1.27x | 0.87x | 1.53x | 1.20xn=2 |
| BetaProvider historical market sensitivity | 0.30 | 0.34 | 0.23 | 0.29n=2 |
YouTube · Q2 2026 · 2026-08-07
YouTube · Q2 2026 · 2026-07-31
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for PFE
Q2 20262026-08-06
Pfizer (PFE): The Beat Was A Decline. And $3.8 Billion Of Pipeline Went To Zero.
Presentation · 2026-08-06 · YouTube
Q1 20262026-05-05
PFE Stock: $14.4B Revenue — Q1 2026 Earnings Analysis
Presentation · 2026-05-05 · YouTube
Q4 20252026-04-13
Charged Alpha | Pfizer (PFE) | Q4 2025 Earnings Deep Dive — Ep. 120
Presentation · 2026-04-13 · YouTube